AstraZeneca Refocuses Risk Management, Elevates Development Oversight
Executive Summary
AstraZeneca's product development and regulatory affairs overhaul will include a review of ongoing Phase III programs for Galida, Cerovive and Symbicort
You may also be interested in...
AstraZeneca Crestor Defense Minimizes Risk Of High Dose, FDA Says
An AstraZeneca newspaper ad defending the safety of Crestor improperly suggests that all doses of rosuvastatin are "just as safe" as other statins, FDA says in a Dec. 21 "untitled" letter to the company
AstraZeneca To Revisit Iressa Dosing Following Failed Survival Study
Inappropriate dose selection is one issue AstraZeneca will examine following Iressa's failure to demonstrate a survival benefit in a Phase IV trial in refractory non-small cell lung cancer, CEO Tom McKillop indicated
AstraZeneca To Revisit Iressa Dosing Following Failed Survival Study
Inappropriate dose selection is one issue AstraZeneca will examine following Iressa's failure to demonstrate a survival benefit in a Phase IV trial in refractory non-small cell lung cancer, CEO Tom McKillop indicated